

- neuropathy, 2683
 oral, 236, 237
 cobalamin malabsorption in, 645
 complications of, 1942, 2347, 2366
 diagnosis of, 1941t, 1942
 barium radiography in, 1939f
 endoscopic, 1897f
 small-intestinal mucosal biopsies in, 1939, 1940t, 1941f, 1942
 tTg antibody test in, 2347
 diseases associated with, 1942
 APS-2, 2346t, 2347, 2347t
 dermatitis herpetiformis, 373, 1942
 diabetes, 1942
 enteropathy-type T-cell lymphoma and, 135e-3
 environmental factors in, 1940
 etiology of, 1940–1942
 genetic considerations in, 373e-7, 373e-8t, 1941–1942, 2347t
 gluten restriction in, 1942
 immunology of, 372e-23, 372e-24t
 incidence of, 269, 1940
 pathology of, 269
 refractory, 1942
 treatment of, 263, 272
 vitamin A deficiency in, 96e-7
 vitamin K deficiency in, 96e-8
 Celiac sprue. *See* Celiac disease
 Cell cycle
 in cancer cells, 102e-1–2, 102e-1t
 checkpoints, 101e-3, 102e-1–2
 DNA replication in, 427
 segregation of mitochondrial DNA in, 85e-2
 Cell free fetal DNA screening, 83e-4
 Cell lysis, in hypothermia, 478e-2
 Cell-mediated immunity
 destruction of tumor cells by, 103e-20
 in HIV infection, 1243t, 1244–1245
 in tuberculosis, 1106
 Cell necrosis, 372e-1
 Cellular metabolism, genetic defects of, 1555t
 Cellular senescence, 102e-3, 102e-8
 Cellular transport, 332e-3
 Cellulitis
 anaerobic bacterial, 995, 1099
 auricular, 228
 burn-wound, 166e-2, 166e-2f
 in cancer patient, 485–486
 diagnosis of, 830
 differential diagnosis of, 366
 E. coli, 1028–1029
 etiology of, 828t, 830
 H. influenzae, 1011
 Nocardia, 1085, 1087t
 pathophysiology of, 827f, 830
 periorbital, 207, 830
 streptococcal, 830, 967–968
 treatment of, 832t, 965t
 Cell wall synthesis inhibitors, 930, 931t, 932f
 Cementum, 236
 Centers for Disease Control and Prevention (CDC)
 infection-control guidance and oversight, 912t, 913
 Vaccines & Immunizations site, 791
 Centipede bite, 2750
 Central cord syndrome, 2652
 Central core disease, 462e-12
 Central cyanosis, 249, 249t. *See also* Cyanosis
 Central fever, 1773
 Central hypoventilation syndrome, 1722
 Central nervous system (CNS)
 cytokine production in, 124
 in hypothermia, 478e-2t
 in hypoxia, 247
 paraneoplastic disorders of. *See* Paraneoplastic syndromes, neurologic
 vasculitis of. *See* Vasculitis, CNS
 Central nervous system (CNS) cancer. *See also* specific types and sites
 brain tumors. *See* Brain tumors
 deaths from, 467t, 470t
 incidence of, 467t
 lymphoma. *See* Primary central nervous system lymphoma (PCNSL)
 metastatic, 1792–1793
 Central nervous system (CNS) infections
 actinomycosis, 1089
 after solid organ transplantation, 463e-3
 anaerobic bacterial, 1098, 1102
 Aspergillus, 441e-9–10f, 1346–1347
 brain abscess. *See* Brain abscess
 in cancer patient, 488, 488t
 Candida, 441e-8f
 cranial epidural abscess, 904–905, 904f
 dementia due to, 2607
 empyema. *See* Subdural empyema
 encephalitis. *See* Encephalitis
 intracranial, 780t, 784
 L. monocytogenes, 983
 M. tuberculosis, 1111
 meningitis. *See* Meningitis
 mucormycosis, 1351, 1351f
 mumps, 231e-2–3
 neurocysticercosis. *See* Neurocysticercosis
 Nocardia, 1085
 nontyphoidal *Salmonella*, 1054
 P. aeruginosa, 1045t, 1046
 rabies. *See* Rabies
 sarcoidosis, 909t
 sporotrichosis, 1354, 1354t
 T. gondii, 1401–1402, 1402f, 1403t
 T. whipplei, 1092
 treatment of, 884–885f, 1102
 VZV, 1183. *See also* Herpes zoster (shingles)
 Central pontine myelinolysis, 301, 1782, 1782f
 Central precocious puberty, 2361. *See also* Precocious puberty
 Central retinal artery occlusion, 201, 201f
 Central retinal vein occlusion, 201–202, 203f
 Central sensitization, 87
 Central sleep apnea, 189, 1727
 Central transtentorial herniation, 1772, 1772f
 Central venous catheter
 clinical procedure tutorial, 481e-1v
 infections related to. *See* Catheter-related bloodstream infections
 for parenteral nutrition, 98e-6
 superior vena cava syndrome and, 1788
 Central venous pressure, 1443, 1748t, 1757
 Centromere-associated proteins, 372e-24t, 2157t
 Centronuclear (myotubular) myopathy, 462e-12, 462e-14
 Cepacia syndrome, 487, 1045t, 1048, 1697
 Cephalixin
 for endocarditis prophylaxis, 826t
 for impetigo, 967
 indications for, 939, 941
 for otitis externa, 228
 for pharyngitis, 232f
 in pregnancy and lactation, 937t
 for staphylococcal skin/soft tissue infections, 345, 768t
 Cephalosporins
 action of, 930, 931t
 adverse effects of, 356, 371, 377, 422, 491
 cross-sensitivity to, 385
 for gonococcal infections, 1008
 indications for, 939–940
 for infections in cancer patient, 491
 for nongonococcal bacterial arthritis, 835
 for plague, 261e-5
 in pregnancy and lactation, 937t
 resistance to
 in *E. coli*, 1026
 in gonococcal infections, 1005
 in gram-negative bacteria, 1026
 in *Klebsiella*, 1033
 mechanisms of, 931t, 933
 for staphylococcal infections, 961
 Cerebellar arteries, occlusion of, 2575–2576, 2575f
 Cerebellar ataxia
 channelopathies in, 444e-2t
 early-onset, 451e-3t
 etiology of, 2626, 2627t
 gait disorders in, 163, 164t
 with muscle coenzyme Q deficiency, 451e-3t
 type 1, 451e-4t
 type 2, 451e-4t
 Cerebellar ataxia, deafness, and narcolepsy, 451e-2t
 Cerebellar ataxia mental retardation, 451e-2t
 Cerebellar degeneration/atrophy
 in alcohol use disorder, 2724
 disease-modifying protein identification in, 87e-2, 87e-3t
 falls in, 147, 164
 gait disorders in, 163, 164t
 paraneoplastic, 372e-25t, 614t, 617–618
 Cerebral amyloid angiopathy, 2583–2584, 2583t, 2602
 Cerebral angiography. *See* Angiography, cerebral
 Cerebral arterial gas embolism, 477e-7
 Cerebral artery(ies)
 anatomy of, 2572f
 aneurysm of, 440e-2f
 middle. *See* Middle cerebral artery
 Cerebral autosomal dominant arteriopathy
 with subcortical infarcts and leukoencephalopathy (CADASIL), 441e-18f, 2568, 2608
 Cerebral blood flow, 1615, 1627, 1778, 1778f
 Cerebral edema
 after subarachnoid hemorrhage, 1785
 high-altitude. *See* High-altitude cerebral edema (HACE)
 in hyponatremia, 300
 Cerebral hemispheres. *See* Brain
 Cerebral ischemia, 2559, 2561f
 Cerebral palsy, 163
 Cerebral perfusion pressure, 1779, 1779f
 Cerebral salt wasting, 299
 Cerebral venous sinuses, 905–906, 905f
 Cerebritis, 901
 Cerebrospinal fluid (CSF)
 leakage of, 110, 110f, 457e-2, 2607
 raised pressure. *See* Intracranial pressure, increased
 Cerebrospinal fluid (CSF) analysis
 in bacterial meningitis, 764, 766t, 887–888, 888t
 in chronic meningitis, 907–909t, 909–910
 in coma, 1775
 in delirium, 170
 in encephalitis, 764, 766t
 in fever of unknown origin, 138
 in HIV infection, 1264
 in MS, 2665
 normal values, 443e-3t, 443e-4, 766t
 in parasitic infections, 245e-6t
 in progressive multifocal leukoencephalopathy, 899
 reference values for, 2767t
 specimen collection and transport, 150e-4t
 in subacute meningitis, 898
 in viral encephalitis, 894
 in viral meningitis, 891
 Cerebrotendinous xanthomatosis, 451e-4t
 Cerebrovascular disease, 2559. *See also* Stroke
 approach to the patient, 2560, 2560f
 deaths from, 6e-1t, 11t
 definition of, 2559
 dementia associated with, 170, 172, 173t, 2602
 global considerations in, 11t, 2559
 imaging studies of. *See* Neuroimaging
 incidence of, 2559
 seizures due to, 2547
 types of, 2559
 vascular anomalies, 2585–2586
 in women, 6e-2f
 Cerivastatin, 246e-3t
 Certolizumab
 adverse effects of, 422, 2146t
 for ankylosing spondylitis, 2172–2173
 for enteropathic arthritis, 2179
 for IBD, 1961
 for rheumatoid arthritis, 2145, 2146t
 Ceruloplasmin, 2519, 2520t
 Cerumen impaction, 220
 Cervical adenopathy, 120e-4, 503, 503f